Read more about our commitment in Oncology

 

Targeting Direct Hits to Cancer Cells

Learn more »

Striving for the Right Tools to Fight Brain Tumors with Kyle Holen

Learn more »

‘Patients Need To Move On With Their Lives’: Q&A With Lori Styles, M.D., Pharmacyclics

Learn more »

 

 

View all of our Oncology press releases:

AbbVie and M2Gen Announce New Collaboration for the Oncology Research Information Exchange Network® (ORIEN) Avatar Research Program

NORTH CHICAGO, Ill. and TAMPA, Fla., March 28, 2017 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, and M2Gen, a leading health informatics solutions company, announced today that AbbVie has joined the Oncology Research Information Exchange Network® (ORIEN) Avatar Research Program. Launched in April of 2016, the ORIEN Avatar Research Program fosters collaboration among key stakeholders in cancer research with the shared goal of discovering and developing novel therapies in clinical trials.   

U.S. FDA Approves IMBRUVICA® (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma

NORTH CHICAGO, Ill., Jan. 19, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) approved IMBRUVICA® (ibrutinib) for the treatment of patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.1 This indication is approved under accelerated approval based on overall response rate (ORR), and continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial. IMBRUVICA is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech, Inc.

AbbVie Announces Four New Global Research Collaborations Focused on Advancing Next-Generation Science

NORTH CHICAGO, Ill., Jan. 9, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced four new collaborations and investments with leading healthcare innovators to advance early-stage research in key therapeutic areas such as oncology and immunology. AbbVie is committed to investing in and developing transformational science and technologies to advance the next-generation of therapies across its robust pipeline in key therapeutic areas.  With more than 50 compounds in clinical development, AbbVie's pipeline spans significant areas of medical need including oncology, immunology, neuroscience and virology.

European Commission Grants Conditional Marketing Approval for AbbVie's VENCLYXTO™ (venetoclax) Monotherapy for Appropriate Patients with Difficult-To-Treat Chronic Lymphocytic Leukaemia

- VENCLYXTO™ (venetoclax) monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor1

Late-Breaking Ibrutinib (IMBRUVICA®) Data Show Complete or Partial Response in Two-Thirds of Patients with Chronic Graft-Versus-Host-Disease, a Frequent and Potentially Life-Threatening Complication of Stem Cell Transplant

NORTH CHICAGO, Ill., Dec. 6, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced positive results from a Phase 2 study (PCYC-1129) evaluating ibrutinib (IMBRUVICA®) in patients with chronic graft-versus-host-disease (cGVHD), a serious and debilitating potential consequence of stem cell or bone marrow transplant,1 who failed prior systemic therapy. The study found ibrutinib demonstrated efficacy, sustained responses and reduced symptom severity, with an overall response rate (ORR) of 67%.2 Final results from this study presented today as a late-breaking oral presentation at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA (abstract #LBA-3). IMBRUVICA, a first-in-class Bruton's tyrosine kinase (BTK) inhibitor, is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech, Inc.